| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5248699 | VIATRIS | Sertraline polymorph |
Aug, 2012
(11 years ago) | |
|
US5248699 (Pediatric) | VIATRIS | Sertraline polymorph |
Feb, 2013
(11 years ago) | |
| US7067555 | VIATRIS | Sertraline oral concentrate |
Oct, 2019
(4 years ago) | |
| US6727283 | VIATRIS | Sertraline oral concentrate |
Oct, 2019
(4 years ago) | |
|
US6727283 (Pediatric) | VIATRIS | Sertraline oral concentrate |
Apr, 2020
(4 years ago) | |
|
US7067555 (Pediatric) | VIATRIS | Sertraline oral concentrate |
Apr, 2020
(4 years ago) | |
Zoloft is owned by Viatris.
Zoloft contains Sertraline Hydrochloride.
Zoloft has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Zoloft are:
- US5248699
- US5248699*PED
- US7067555
- US6727283
- US6727283*PED
- US7067555*PED
Zoloft was authorised for market use on 07 December, 1999.
Zoloft is available in tablet;oral, concentrate;oral dosage forms.
Zoloft can be used as treatment of disorders of the serotonergic system such as depression and anxiety-related disorders.
The generics of Zoloft are possible to be released after 11 April, 2020.
Drugs and Companies using SERTRALINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 1999
Treatment: Treatment of disorders of the serotonergic system such as depression and anxiety-related disorders
Dosage: CONCENTRATE;ORAL; TABLET;ORAL
ZOLOFT family patents
